venetoclax: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
venetoclax: clinical details
Prescribing considerations
- Initiate and supervise treatment through clinicians experienced in anticancer therapy.
- Assess tumour burden, renal function, comorbidities and other tumour lysis syndrome risk factors before initiation or re-initiation.
- Provide risk-appropriate hydration, anti-hyperuricaemic prophylaxis, laboratory monitoring and, where indicated, hospital observation.
- Review all concomitant medicines for CYP3A, P-gp, BCRP and OATP interactions.
- Consider infection history, hepatic impairment, vaccination plans, pregnancy prevention and fertility counselling.
- Reduced renal function increases tumour lysis syndrome risk; severe hepatic impairment increases venetoclax exposure and requires specialist management.
Contraindications and cautions
- Hypersensitivity to venetoclax or an excipient.
- In CLL, concomitant strong CYP3A inhibitors during treatment initiation and titration.
- Preparations containing St John’s wort.
Monitoring
- Tumour burden and baseline potassium, urate, phosphate, calcium and creatinine.
- Blood chemistry around initiation, treatment changes and whenever tumour lysis syndrome is suspected.
- Full blood count throughout treatment, with prompt assessment of neutropenia, thrombocytopenia and anaemia.
- Clinical signs of infection, bleeding, tumour lysis syndrome and other toxicity.
- Renal and hepatic function and changes to interacting medicines.
- In AML, treatment response and blood-count recovery should inform toxicity management.
Clinical pharmacology
Venetoclax is a selective BCL-2 inhibitor that promotes mitochondrial apoptosis in susceptible tumour cells. It is predominantly metabolised by CYP3A and is a substrate of P-gp and BCRP; food increases exposure and helps avoid reduced efficacy.
Formulation and product differences
- The selected product is a pale-yellow, round film-coated tablet marked “V” on one side and “10” on the other.
- Tablets must be swallowed whole and are not suitable for crushing, chewing or splitting.
- The formulation is essentially sodium-free.
venetoclax preparations and strengths
Tablet
Route: Oral
Strengths: 10 mg, 50 mg, 100 mg
venetoclax interactions
Venetoclax has clinically important interactions. The specialist team should review prescribed, non-prescription and herbal products before treatment and whenever medicines change.
Strong or moderate CYP3A inhibitors, including clarithromycin, azole antifungals, ritonavir, ciprofloxacin, diltiazem and verapamil
These can substantially increase venetoclax exposure and the risk of tumour lysis syndrome or other toxicity; some combinations are contraindicated during CLL treatment initiation and titration.
CYP3A inducers, including rifampicin, carbamazepine, phenytoin and modafinil
These may lower venetoclax exposure and reduce effectiveness, so concomitant use should generally be avoided.
St John’s wort
This herbal preparation is contraindicated because it may reduce venetoclax exposure and effectiveness.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.